CoChat

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

Colak, S, Zimberlin, C D, Fessler, E, Hogdal, L, Prasetyanti, P R, Grandela, C M, Letai, A, Medema, J P · 2014 · Cell Death & Differentiation
Cited by 114

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2014.37

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 42

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. · DOI · Paper page
  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917. · DOI · Paper page
  3. Van Cutsem E, Nordlinger B, Cervantes A, Group EGW. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21 (Suppl 5): v93–v97. · DOI · Paper page
  4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350: 2335–2342. · DOI · Paper page
  5. Punt CJ, Tol J . More is less—combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009; 6: 731–733. · DOI
  6. Kemper K, Grandela C, Medema JP . Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010; 1: 387–395. · DOI
  7. Todaro M, Francipane MG, Medema JP, Stassi G . Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010; 138: 2151–2162. · DOI · Paper page
  8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111–115. · DOI · Paper page
  9. O'Brien CA, Pollett A, Gallinger S, Dick JE . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106–110. · DOI · Paper page
  10. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389–402. · DOI · Paper page
  11. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468–476. · DOI · Paper page
  12. Medema JP . Cancer stem cells: the challenges ahead. Nat Cell Biol 2013; 15: 338–344. · DOI · Paper page
  13. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3: e2428. · DOI · Paper page
  14. de Bruin EC, Medema JP . Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008; 34: 737–749. · DOI · Paper page
  15. Ryan JA, Brunelle JK, Letai A . Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA 2010; 107: 12895–12900. · DOI · Paper page
  16. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129–1133. · DOI · Paper page
  17. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344–355. · DOI · Paper page
  18. Rooswinkel RW, van de Kooij B, Verheij M, Borst J . Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012; 3: e366. · DOI
  19. Zhai D, Jin C, Satterthwait AC, Reed JC . Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419–1421. · DOI · Paper page
  20. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681. · DOI · Paper page
  21. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807–5816. · DOI · Paper page
  22. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208. · DOI · Paper page
  23. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol 2013; 9: 390–397. · DOI · Paper page
  24. Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 2011; 10: M111 011353. · DOI · Paper page
  25. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171–185. · DOI · Paper page
  26. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351–365. · DOI · Paper page
  27. Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 1984; 81: 7166–7170. · DOI · Paper page
  28. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B . Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237–241.
  29. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G . Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145: 1036–1040.
  30. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517–531. · DOI · Paper page
  31. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856–859. · DOI · Paper page
  32. Weiss LM, Warnke RA, Sklar J, Cleary ML . Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. New Engl J Med 1987; 317: 1185–1189. · DOI · Paper page
  33. Aisenberg AC, Wilkes BM, Jacobson JO . The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988; 71: 969–972. · doi:10.1182/blood.v71.4.969.969
  34. Ogura E, Senzaki H, Yamamoto D, Yoshida R, Takada H, Hioki K et al. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep 1999; 6: 365–369.
  35. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967–969. · DOI · Paper page
  36. Wilson BJ, Schatton T, Zhan Q, Gasser M, Ma J, Saab KR et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res 2011; 71: 5307–5316. · DOI · Paper page
  37. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP . Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 2012; 30: 2378–2386. · DOI · Paper page
  38. Kemper K, Rodermond H, Colak S, Grandela C, Medema JP . Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 2012; 17: 528–537. · DOI
  39. Vandenberg CJ, Cory S . ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285–2288. · DOI · Paper page
  40. Davids MS, Letai A . ABT-199: taking dead aim at BCL-2. Cancer Cell 2013; 23: 139–141. · DOI
  41. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006–4017. · DOI · Paper page
  42. Hu Y, Smyth GK . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70–78. · DOI · Paper page

Cited by

See all 114

Metadata

Authors
Colak, S., Zimberlin, C. D., Fessler, E., Hogdal, L., Prasetyanti, P. R., Grandela, C. M., Letai, A., & Medema, J. P.
Venue
Cell Death & Differentiation
Published
2014-03-28
Volume
21
Issue
7
Pages
1170-1177
ISSN
  • 1350-9047
  • 1476-5403
Cited by
114
References
6
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. https://app.cochat.ai/papers/10.1038/cdd.2014.37
The paper
Colak, S., Zimberlin, C. D., Fessler, E., Hogdal, L., Prasetyanti, P. R., Grandela, C. M., Letai, A., & Medema, J. P. (2014). Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death & Differentiation. https://doi.org/10.1038/cdd.2014.37

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.